Considerations Following Locoregional Therapy in HCC

Video

Considerations Following Locoregional Therapy in HCC

May 2015

  • 64-year old obese female presented with fatigue and unexplained weight loss
  • History of nonalcoholic fatty liver disease (NAFLD), then nonalcoholic steatohepatitis (NASH)
  • Lab results: AFP= 1,500 IU/ml
  • ECOG=1; Child-Pugh A
  • CT revealed 1 large liver mass, right side of liver close to a major blood vessel
  • No extrahepatic disease
  • Liver-directed therapy with DEB-TACE was performed
  • Patient reported abdominal pain following DEB-TACE and required analgesics; low-grade fever
  • Patient had a complete response
  • AFP= 200 IU/ml at follow up

February 2017

  • Follow-up imaging showed progression and evidence of bone metastases
  • Therapy was initiated with sorafenib at 400 mg BID
  • Follow-up testing showed liver decompensation
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis